A novel immunomodulatory molecularly targeted strategy for refractory Hodgkin's lymphoma
about
Prospects and pitfalls of personalizing therapies for sarcomas: from children, adolescents, and young adults to the elderlyExpression of Sirt1 and FoxP3 in classical Hodgkin lymphoma and tumor infiltrating lymphocytes: Implications for immune dysregulation, prognosis and potential therapeutic targeting.Personalized comprehensive molecular profiling of high risk osteosarcoma: Implications and limitations for precision medicinePuquitinib mesylate, an inhibitor of phosphatidylinositol 3-kinase p110δ, for treating relapsed or refractory non-Hodgkin's lymphoma.Morphoproteomics and biomedical analytics confirm the mTORC2/Akt pathway as a resistance signature and activated ERK and STAT3 as concomitant prosurvival/antiapoptotic pathways in metastatic renal cell carcinoma (RCC) progressing on rapalogs: pathogDefining Clinical Response Criteria and Early Response Criteria for Precision Oncology: Current State-of-the-Art and Future Perspectives.Novel treatment concepts in Hodgkin lymphoma.Chidamide and decitabine can synergistically induce apoptosis of Hodgkin lymphoma cells by up-regulating the expression of PU.1 and KLF4.Determination of Puquitinib in Human Plasma by HPLC-ESI MS/MS: Application to Pharmacokinetic Study.
P2860
Q27025344-9A36C826-8A51-485A-8951-DD3ABB68190CQ36375393-402B1705-2D14-4B13-A370-A2C2785F638BQ36562114-8DC50090-B658-4328-BC3A-55800197BB72Q36685569-51DF3968-16E9-4644-A932-8E0BB9B9DE6AQ37520310-70749E56-E916-4E47-A7A2-F6F73FC4DD8EQ37729968-806DF8F4-DC03-47B8-A1EA-89322D350EC2Q39043082-D078CB30-E06B-49FF-B144-6A4920B2AB34Q43269281-9DEE0572-7EEC-4BE0-8E52-AE34D97216DEQ52665380-B80ED005-0D9C-4777-9E73-3C7F6F19B44C
P2860
A novel immunomodulatory molecularly targeted strategy for refractory Hodgkin's lymphoma
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2014
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
A novel immunomodulatory molecularly targeted strategy for refractory Hodgkin's lymphoma
@en
A novel immunomodulatory molecularly targeted strategy for refractory Hodgkin's lymphoma.
@nl
type
label
A novel immunomodulatory molecularly targeted strategy for refractory Hodgkin's lymphoma
@en
A novel immunomodulatory molecularly targeted strategy for refractory Hodgkin's lymphoma.
@nl
prefLabel
A novel immunomodulatory molecularly targeted strategy for refractory Hodgkin's lymphoma
@en
A novel immunomodulatory molecularly targeted strategy for refractory Hodgkin's lymphoma.
@nl
P2093
P2860
P356
P1433
P1476
A novel immunomodulatory molecularly targeted strategy for refractory Hodgkin's lymphoma
@en
P2093
Anas Younes
David Hong
Jamie Buryanek
Mary F McGuire
Robert E Brown
Vivek Subbiah
P2860
P304
P356
10.18632/ONCOTARGET.1468
P407
P50
P577
2014-01-01T00:00:00Z